F S&P 500
4,997.75 -51.25 (-1.02%) F Dow Jones
37,662.00 -345.00 (-0.91%) F Nasdaq
17,328.50 -218.75 (-1.25%) E-mini Russell 2000 Index Futur
1,934.80 -23.30 (-1.19%) Petróleo
84.70 +1.97 (+2.38%) Oro
2,404.90 +6.90 (+0.29%)
Dyne Therapeutics, Inc. (DYN)
Fuera de horario:
Dyne Therapeutics, Inc.
1560 Trapelo Road
Waltham, MA 02451
United States
781 786 8230
https://www.dyne-tx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 141
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Ms. Susanna Gatti High M.B.A. | Chief Operating Officer | 754.1k | N/D | 1968 |
| Dr. Jonathan McNeill M.D. | Chief Business Officer | 662.34k | N/D | 1985 |
| Mr. John G. Cox M.B.A. | CEO, President & Director | N/D | N/D | 1963 |
| Dr. Romesh Subramanian Ph.D. | Co-Founder & Advisor | 565.17k | N/D | 1965 |
| Mr. Richard William Scalzo M.B.A. | Senior VP and Head of Finance & Administration | N/D | N/D | 1986 |
| Mr. John Najim M.B.A. | Chief Technical Officer | N/D | N/D | N/D |
| Dr. Oxana Beskrovnaya Ph.D. | Chief Scientific Officer | 631.08k | N/D | 1961 |
| Ms. Amy Reilly | Senior VP and Head of Corporate Communications & Investor Relations | N/D | N/D | 1974 |
| Mr. Daniel Wilson | Senior VP & Head of Legal | N/D | N/D | 1972 |
| Ms. Kate Mitchell | VP & Head of Human Resources | N/D | N/D | N/D |
Descripción
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Dyne Therapeutics, Inc. a partir del 1 de abril de 2024 es 9. Las puntuaciones principales son Auditoría: 7; Junta: 7; Derechos del accionista: 8; Compensación: 10.
